Proclara Biosciences

Proclara Biosciences (formerly NeuroPhage Pharm) is a pharmaceutical company whose mission is to advance the treatment of chronic neurodegenerative diseases through a novel, multi-target approach to reducing pathologic deposits misfolded proteins.In September 2016, NeuroPhage Pharm relaunched under the name Proclara Biosciences.In September 2016, the company secured $47 million through series E financing,.In March 2014, NeuroPhage raised $17 million in a series D financing round. In January 2015, the company closed $10 million from new investors in an extension of the series D financing round. The funds were to be used to advance the company's drug NPT-088 into clinical trials.In May 2013, NeuroPhage raised $6.4 million in a private equity financing round.In March 2011, NeuroPhage raised $12.4 million in a series B financing round, which included Shire, bringing the total raised by the company since 2007 to $19.6 million. In M